Year : 2020  |  Volume : 13  |  Issue : 4  |  Page : 334--336

Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium


Adhi Arya, Sushil Azad, Radhakrishnan Sitaraman 
 Department of Pediatric Cardiology, Fortis Escorts Heart Institute, New Delhi, India

Correspondence Address:
Dr. Adhi Arya
Fortis Escorts Heart Institute New Delhi
India

Heart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are differences in the etiology, clinical course, and outcome of pediatric heart failure as compared to adult, thus the results of adult heart failure trials cannot be simply extrapolated to pediatric patients. There have been a lot of newer drugs for adults with heart failure, but there is a void for pediatric population with heart failure due to many reasons. Early results of multi-centric randomized control PANORAMA HF Trial and subsequent Food and Drug Administration approval for Angiotensin Receptor and Neprylisin Inhibitor (Sacubitril / Valsartan) for pediatric patients have tried to fill in this void and paved the way for a newer class of drugs for heart failure with proven benefits in pediatric patients.


How to cite this article:
Arya A, Azad S, Sitaraman R. Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium.Ann Pediatr Card 2020;13:334-336


How to cite this URL:
Arya A, Azad S, Sitaraman R. Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium. Ann Pediatr Card [serial online] 2020 [cited 2020 Nov 25 ];13:334-336
Available from: https://www.annalspc.com/article.asp?issn=0974-2069;year=2020;volume=13;issue=4;spage=334;epage=336;aulast=Arya;type=0